Last reviewed · How we verify

Prevenar 13 + Pneumovax 23 — Competitive Intelligence Brief

Prevenar 13 + Pneumovax 23 (Prevenar 13 + Pneumovax 23) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Pneumococcal vaccine combination. Area: Immunology / Infectious Disease.

marketed Pneumococcal vaccine combination Immunology / Infectious Disease Biologic Live · refreshed every 30 min

Target snapshot

Prevenar 13 + Pneumovax 23 (Prevenar 13 + Pneumovax 23) — Poitiers University Hospital. This sequential pneumococcal vaccination regimen primes and boosts the immune system against 13 common pneumococcal serotypes (Prevenar 13) followed by 23 serotypes (Pneumovax 23) to provide broad protection against pneumococcal disease.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Prevenar 13 + Pneumovax 23 TARGET Prevenar 13 + Pneumovax 23 Poitiers University Hospital marketed Pneumococcal vaccine combination

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Pneumococcal vaccine combination class)

  1. Poitiers University Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Prevenar 13 + Pneumovax 23 — Competitive Intelligence Brief. https://druglandscape.com/ci/prevenar-13-pneumovax-23. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: